

ANDREW M. CUOMO Governor HOWARD A. ZUCKER, M.D., J.D. Commissioner

SALLY DRESLIN, M.S., R.N. Executive Deputy Commissioner

Medicaid Pharmacy Prior Authorization Programs Update

On November 19, 2015, the New York State Medicaid Drug Utilization Review (DUR) Board recommended changes to the Medicaid pharmacy prior authorization programs. **Effective January 21, 2016**, the fee-for-service pharmacy program will implement the following parameters:

Drugs for Opioid Induced Constipation (OIC)

- Confirm diagnosis for the FDA-approved or compendia-supported indication(s):
 - o Absence of covered diagnosis in patient's claim history will require prescriber involvement
- Step therapy:
 - Trial with an osmotic laxative, a stimulant laxative and a stool softener prior to use of lubiprostone (Amitiza®), methylnaltrexone (Relistor®), or naloxegol (Movantik™)
- Quantity limits based on FDA-approved labeling:
 - Lubiprostone (Amitiza®):
 - 2 capsules per day (60 capsules per 30 days)
 - Methylnaltrexone (Relistor[®]):
 - Single-use vials and syringes (8 mg and 12 mg):
 - 1 vial/syringe per day (30 vials/syringes per 30 days)
 - Kits (contains 7 pre-filled single-use syringes in 8 mg and 12 mg):
 - 4 kits per 28 days
 - o Naloxegol (Movantik™):
 - 1 tablet per day (30 tablets per 30 days)

Kalydeco (ivacaftor), Orkambi (ivacaftor/lumacaftor)

- Confirm diagnosis for the FDA-approved or compendia-supported indication(s). Genetic testing required to verify appropriate mutation.
 - o Absence of covered diagnosis in patient's claim history will require prescriber involvement.

Erythropoietin-Stimulating Agents (ESAs)

- Confirm diagnosis for the FDA-approved or compendia-supported indication(s):
 - Absence of covered diagnosis in patient's claim history will require prescriber involvement

Daraprim (pyrimethamine)

- Confirm diagnosis for the FDA-approved or compendia-supported indications:
 - o Absence of covered diagnosis in patient's claim history will require prescriber involvement.
- Require concurrent utilization of leucovorin.

For more detailed information on the DURB, please refer:

http://www.health.ny.gov/health_care/medicaid/program/dur/index.htm

Below is a link to the most up-to-date information on the Medicaid FFS Pharmacy Prior Authorization (PA) Programs. This document contains a full listing of drugs subject to the Medicaid FFS Pharmacy Programs:

https://newyork.fhsc.com/downloads/providers/NYRx PDP PDL.pdf

To obtain a PA, please contact the clinical call center at 1-877-309-9493. The clinical call center is available 24 hours per day, 7 days per week with pharmacy technicians and pharmacists who will work with you, or your agent, to quickly obtain a PA.

Medicaid enrolled prescribers can also initiate PA requests using a web-based application. PAXpress® is a web based pharmacy PA request/response application accessible through a new button, "PAXpress", located on eMedNY.org under the MEIPASS button.

Additional information, such as the Medicaid Standardized PA form and clinical criteria, is available at the following websites:

http://www.nyhealth.gov or http://newyork.fhsc.com or http://www.eMedNY.org